The surface presentation of peptides by major histocompatibility complex (MHC) class I molecules is critical to CD8 + T cellmediated adaptive immune responses. Aminopeptidases have been linked to the editing of peptides for MHC class I loading, but carboxy-terminal editing is thought to be due to proteasome cleavage. By analysis of wild-type mice and mice genetically deficient in or overexpressing the dipeptidase angiotensin-converting enzyme (ACE), we have now identified ACE as having a physiological role in the processing of peptides for MHC class I. ACE edited the carboxyl terminus of proteasome-produced MHC class I peptides. The lack of ACE exposed new antigens but also abrogated some self antigens. ACE had substantial effects on the surface expression of MHC class I in a haplotype-dependent manner. We propose a revised model of peptide processing for MHC class I by introducing carboxypeptidase activity into the process.
A r t i c l e s
The surface presentation of peptides by major histocompatibility complex (MHC) class I molecules is critical to transplant rejection and to almost all CD8 + T cell adaptive immune responses. The loading of MHC class I with peptides is a multistep process [1] [2] [3] . Most MHC class I peptides begin as proteasomal degradation products of cytosolic proteins 4 . Once transported to the endoplasmic reticulum by the transporter associated with antigen processing (TAP), peptides are not selected randomly by MHC class I molecules but instead are chosen by length and sequence 5 , with peptidases editing the raw peptide pool 4, 6 . Aminopeptidases, particularly ERAP (endoplasmic reticulum aminopeptidase associated with antigen processing), have been linked to the processing of MHC class I peptides 7, 8 , but it is generally thought that the proteasome, not carboxypeptidases, makes the final cut of the carboxyl (C) terminus for MHC class I peptides 9, 10 . Nardilysin and thimet oligopeptidase have been found to trim the C terminus 11 , but these enzymes work partly in a proteasome-independent manner and their contribution to the general MHC class I peptide repertoire is not clear.
Angiotensin-converting enzyme (ACE) is a zinc-dependent carboxyl dipeptidase that belongs to the gluzincin family. The enzyme has an important role in the regulation of blood pressure through its C-terminal cleavage of angiotensin I to angiotensin II, but ACE has wide substrate specificity, including such diverse peptides as bradykinin, substance P and Ac-SDKP 12, 13 . Typically, ACE is a cell membraneassociated type I ectoenzyme 13 . However, functionally active ACE is found in the endoplasmic reticulum 14 . ACE is expressed by many different tissues, and 'professional' antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), make ACE [15] [16] [17] . It has been reported that ACE can digest peptides for MHC class I presentation 14, 18, 19 , but that work was done under conditions of ACE overexpression, and the natural, physiological role of ACE in this process has remained unclear. Here, by studying mice with high, normal or no ACE expression, we show that under physiological conditions, ACE edits the C terminus of MHC class I peptides.
RESULTS

ACE expression increases with APC maturation
To determine whether ACE participates in antigen presentation, we first evaluated ACE expression in the differentiation of monocytes to macrophages, as the antigen-presentation machinery is usually upregulated as APCs mature. We cultured wild-type bone marrow CD11b + Ly6C hi Ly6G -F4/80 lo monocytes with macrophage colonystimulating factor (M-CSF) for 4 d, by which time almost all the cells had a macrophage morphology and had upregulated F4/80. The differentiation of monocytes to macrophages resulted in tenfold more ACE mRNA (Fig. 1a) . ACE mRNA was even greater in abundance in thioglycollate-induced peritoneal macrophages (TPMs), an inflammatory macrophage type with higher expression of MHC class II and the costimulatory molecules CD80 and CD86 than M-CSF-induced macrophages (Supplementary Fig. 1 ). Interferon-γ (IFN-γ) is a strong stimulant for the upregulation of antigen processing and presentation, which is accompanied by the upregulation of many components of the MHC class I pathway 20 . We found that IFN-γ upregulated ACE mRNA in TPMs and skin-derived fibroblasts and resulted in much A r t i c l e s more ACE mRNA and ACE protein in bone marrow-derived DCs (Fig. 1b) . Furthermore, stimulation with the Toll-like receptor 4 ligand lipopolysaccharide moderately upregulated ACE expression in DCs ( Supplementary Fig. 2 ). However, we did not find such upregulation with the Toll-like receptor 3 ligand poly(I:C). Finally, in wild-type mice infected with Listeria monocytogenes, ACE was substantially upregulated after 2 d in splenic DCs and red-pulp macrophages ( Fig. 1c) but not in T cells or B cells. Thus, under several different conditions, the maturation of APCs was associated with higher ACE expression.
ACE affects the surface expression of MHC class I
Individual MHC class I molecules select peptides with a 'preferred' consensus motif and thus bind distinct peptide repertoires 5 . If ACE affects the peptide repertoire, then the enzyme may affect surface expression of MHC class I proteins. We assessed the surface amount of H-2K b and H-2D b on ACE-deficient cells from Ace −/− mice 21 , ACE wild-type cells (Ace +/+ ) and cells overexpressing ACE. For the last group, we used cells from two unique mouse strains, ACE 10 (ref. 22) and Pd, which overexpress ACE in macrophages and DCs, respectively ( Supplementary Fig. 3 ). Among the peritoneal F4/80 hi macrophages and the splenic CD11c hi DCs, there was a 17% greater mean fluorescence intensity of H-2K b and 31% more H-2D b on Ace −/− cells than on their Ace +/+ counterparts ( Fig. 2a) . In contrast, both molecules were lower in abundance on cells overexpressing ACE (16% for H-2K b and 22% for H-2D b ). We found a similarly greater abundance of H-2K b and H-2D b on Ace −/− total splenocytes ( Supplementary Fig. 4a ). Furthermore, IFN-γ-treated Ace −/− skin-derived fibroblasts expressed much more surface H-2K b and H-2D b than did IFN-γ-treated Ace +/+ cells (Fig. 2b) . Thus, our analysis of mice with high, normal or no ACE expression indicated an inverse relationship between ACE abundance and the quantity of MHC class I on the cell surface.
To confirm the relationship between ACE expression and MHC class I expression, we first transfected mouse fibroblasts (L cells) expressing H-2K b (L.K b cells) with an expression construct for catalytically active ACE or with mutated ACE cDNA encoding mutant ACE (mACE) which the two catalytic domains of ACE were rendered inactive by point mutations. Transfection of the catalytically active ACE construct resulted in 20% lower surface expression of H-2K b than that of cells expressing mACE ( Fig. 2c) . Moreover, in wild-type C57BL/6 mice given the pharmacological ACE inhibitor ramipril for 6 d, splenocyte expression of H-2K b and H-2D b was 34% and 43% higher, respectively ( Fig. 2d) . To investigate whether ACE also affects the presentation of other MHC class I molecules, we overexpressed ACE in L929 mouse fibroblasts (H-2 k haplotype ) and A20 mouse B cell lymphoma cells (H-2 d haplotype). This resulted in 19% more H-2K k , 15% less H-2D k and 12% less H-2K d , whereas H-2D d barely changed ( Fig. 2e) . In BALB/c mice treated with ramipril, splenic DC H-2K d and H-2D d were 12% and 9% higher, whereas H-2L d was unaffected ( Supplementary  Fig. 4b ). Thus, ACE has considerable effects on surface expression of MHC class I in a haplotype-dependent manner. 1 0 8 0 VOLUME 12 NUMBER 11 NOVEMBER 2011 nature immunology A r t i c l e s with brefeldin A. This showed that the rate of loss of surface H-2K b and H-2D b was similar in total peritoneal cells from Ace −/− or Ace +/+ mice (Fig. 3a) . Next we measured the de novo appearance of MHC class I on the cell surface. For this, we stripped away the existing cell surface MHC class I-peptide complexes by short-term treatment with acid. We then returned the cells to medium with a normal pH (7.4) and measured the time-dependent recovery of MHC class I molecules at the cell surface ( Fig. 3b) . This recovery was 10-20% faster in Ace −/− cells than in Ace +/+ cells. These data suggested that part of the reason for the higher surface expression of MHC class I in Ace −/− cells may have been faster assembly of new MHC-peptide complexes but not more peptide-dependent stability of MHC class I in these cells.
Peptide supply and MHC class I stability
ACE edits the MHC class I peptide repertoire
Because the abundance of ACE directly affected the surface expression of MHC class I-peptide complexes, we next assessed the nature of the peptides presented by MHC class I when ACE expression changed. One means of detecting differences in the MHC class I-peptide repertoire is cross-immunization 23 . Specifically, we immunized female Ace +/+ mice with peritoneal macrophages from male Ace +/+ mice or male ACE 10 mice. The advantage of this sex disparity is the measurement of the responses of CD8 + T cells from female mice to the HY peptides Smcy and Uty, which are the Y chromosome-specific H-2D b epitopes 24 . At 10 d, we killed the female mice and expanded their splenocyte populations in culture with cells equivalent to those used to immunize the mice (booster). After 7 d of culture, we further restimulated the cells with APCs (Ace +/+ macrophages from female mice) loaded with either Smcy or Uty. Then, 5 h later, we quantified peptide-specific IFN-γ-secreting CD8 + T cells by intracellular staining and flow cytometry ( Fig. 4a ). There was a twofold greater response to Smcy and a threefold greater response to Uty by CD8 + T cells from female mice immunized with ACE 10 cells than by CD8 + T cells from those immunized with Ace +/+ cells. These data would be consistent with a difference in the number of Uty or Smcy peptides presented by H-2D b on the Ace +/+ and ACE 10 macrophages from male mice used for immunization. Indeed, when we examined surface presentation of Uty with the Uty-specific cytotoxic T lymphocyte (CTL) clone CTL-10, there was much more presentation of Uty by H-2D b on ACE 10 macrophages than on Ace +/+ macrophages 25 (Supplementary  Fig. 5 ). When we restimulated the splenocytes from the immunized female Ace +/+ mice not with peptides but with macrophages from male mice equivalent to those used for the original immunization, there was again a greater response after immunization, expansion and restimulation with cells from male ACE 10 mice than after similar treatment with cells from male Ace +/+ mice. However, when both the boosting and the restimulation were done with macrophages from female Ace +/+ mice or female ACE 10 mice, there was no CD8 + T cell response. These data suggested that ACE overexpression in the ACE 10 cells changed (in this case, increased) presentation of the Uty and Smcy epitopes but that it did not create any new epitopes, as indicated by the lack of response of cells from the immunized female Ace +/+ mice to restimulation with cells from female ACE 10 mice.
By a similar approach, we next investigated the presentation of self antigen by Ace −/− cells. In these experiments, female Ace +/+ mice immunized with cells from male Ace −/− mice had a CD8 + T cell response to Uty and Smcy that was only 50% that of female Ace +/+ mice immunized with cells from male Ace +/+ mice (Fig. 4b) . However, after restimulation with macrophages from male mice, there was a much stronger response in the female Ace +/+ mice immunized with Ace −/− cells (29% IFN-γ + ) than in those immunized with Ace +/+ cells (4% IFN-γ + ). Furthermore, after immunization of female Ace +/+ mice with cells from male Ace −/− mice, followed by expansion and restimulation with cells from female Ace −/− mice, there was also a very robust CD8 + T cell response (23% IFN-γ + ) not present after immunization of female Ace +/+ mice with cells from male Ace +/+ mice followed by expansion and restimulation with cells from female Ace +/+ mice (1% IFN-γ + ). We obtained similar results when the immunizing and stimulating cells were total splenocytes instead of macrophages ( Supplementary  Fig. 6a ). The finding that cells from female Ace −/− mice elicited such a strong response in female Ace +/+ mice indicated that the Ace −/− cells presented a surface repertoire containing some epitopes distinct from those of the Ace +/+ repertoire. In support of that argument, the final yield of CD8 + T cells from Ace +/+ mice after immunizing and boosting with Ace −/− cells was substantially more than that of equivalent mice treated with Ace +/+ cells (Supplementary Fig. 6a,b) .
A potential concern of the data reported above is that although Ace −/− mice are highly inbred to the C57BL/6 strain, it is conceivable that the cross-immunization response may be directed toward minor histocompatibility loci of strain 129. To investigate this, we sought to determine whether treatment with an inhibitor of ACE (ramipril) in vivo would change the MHC class I peptide repertoire of Ace +/+ cells. We immunized Ace +/+ mice and boosted their splenocytes with Ace −/− macrophages from mice of the same sex as the recipients. However, for the final restimulation step, we used either Ace +/+ cells from syngeneic mice or Ace +/+ cells from syngeneic mice treated with ramipril for 6 d (Supplementary Fig. 7) . Although it was less robust than the response to Ace −/− cells, the cells from Ace +/+ mice treated with ramipril activated a substantial population of CD8 + T cells, a result we did not obtain with cells from untreated Ace +/+ mice (9.1% versus 1.4%). Thus, pharmacological inhibition of ACE activity caused a substantial shift in the MHC class I peptide repertoire presented by syngeneic cells, which mimicked the Ace −/− phenotype.
To further investigate if peptides presented by MHC class I proteins were responsible for the cross-immunization results, we determined whether the CD8 + T cell response of Ace +/+ mice to Ace −/− cells could be inhibited when we preblocked the Ace −/− cells used for restimulation with antibody B22.249 (an H-2D b -specific antibody). Antibody B22.249 inhibited this response by almost 60% (Supplementary  Fig. 7) . We assume a substantial part of the remaining activity was due to presentation by H-2K b , which was not blocked in the experiment. Thus, the magnitude of the effect obtained with this antibody to H-2D b complemented the results obtained by the pharmacological approach in showing that the immune response was not directed toward minor histocompatibility molecules but was instead directed toward antigens presented by MHC class I molecules.
To further investigate whether Ace −/− mice expressed all the peptide epitopes present in wild-type mice or whether some wild-type epitopes were lost, we immunized, boosted and restimulated Ace −/− mice and cells with macrophages from Ace +/+ or Ace −/− mice (Fig. 4c) . In all conditions, the cells used for immunization were from mice of the same sex as the recipients. Although Ace −/− mice immunized with Ace −/− cells showed essentially no response (about 1% IFN-γ + CD8 + T cells), the equivalent mice immunized with Ace +/+ cells showed a very strong response (22% IFN-γ + ). Also, the final yield of CD8 + T cells from Ace −/− mice was much greater after immunization and boosting with Ace +/+ macrophages than after similar use of Ace −/− cells (Supplementary Fig. 6c ). As all mice were on the C57BL/6 background, these data supported the conclusion that the surface peptide repertoires of Ace +/+ and Ace −/− cells were different from each other.
Another way to assess presentation of peptides is to examine T cell antigen receptor (TCR) diversity. If the presence or the absence of ACE were associated with different processing of peptide antigens, this might be reflected by differences in the use of the TCR β-chain variable region (V β ). To investigate this, we assessed the CD8 + T cell V β repertoire in splenocytes isolated from Ace +/+ and Ace −/− mice. We also examined V β use after acute infection with mouse polyomavirus ( Supplementary Fig. 8) , as ACE has different effects on the expression of polyomavirus large T antigen and middle T antigen 14 . We found differences between Ace +/+ and Ace −/− mice in V β use both before and 8 d after infection with polyomavirus ( Fig. 4d) . For example, before infection, V β chain 3 was more frequent in CD8 + T cells from Ace +/+ mice than in those from Ace −/− mice. However, after infection, this was reversed, with Ace −/− mice having a greater frequency of V β chain 3. We noted differences in the use of V β chains 3, 7, 8.1 and 8.2, 9 and 10 b .
ACE edits self antigens
The general differences between Ace +/+ and Ace −/− mice in MHC class I peptide repertoires led us to investigate their different presentations of individual peptides. We thus measured a panel of minor histocompatibility antigens specifically expressed by C57BL/6 mice. We quantified individual minor histocompatibility antigens through the use of antigen-specific CTL clones. When we used IFN-γ-primed fibroblasts from Ace +/+ and Ace −/− mice, we observed that the Ace −/− cells were profoundly deficient in H7 a and H3a a antigens but had higher expression of H47 a and H13 a (Fig. 5a) . Consistent with that, ACE 10 macrophages presented more H7 a and H3a a but less H47 a than did the equivalent Ace +/+ cells (Fig. 5b) . Expression of H13 a was similar in ACE 10 and Ace +/+ cells. These results indicated that ACE directly affected the presentation of self antigen, with positive or negative effects.
ACE affects the presentation of viral antigens
We also measured the effect of ACE on the presentation on polyomavirus-derived antigens. At 8 d after infection of Ace +/+ and Ace −/− mice 1 0 8 2 VOLUME 12 NUMBER 11 NOVEMBER 2011 nature immunology A r t i c l e s with polyomavirus, we measured the splenic CD8 + T cell responses to the following three dominant or subdominant polyomavirus antigens: LT359-368 (presented by H-2D b ), MT246-253 (presented by H-2K b ) and LT638-646 (presented by H-2D b ) 26 (Fig. 6a) . Ace −/− mice had lower responses than their Ace +/+ littermates to the dominant antigen LT359-368 and subdominant antigen MT246-253 but had a greater response to the subdominant epitope LT638-646.
To directly measure the presentation of viral antigens by APCs, we infected mice with the polyomavirus strain PyV.OVA-I, which expresses the H-2K b -dominant ovalbumin peptide SIINFEKL (SKL) in the sequence of the polyomavirus middle T antigen 27 . At 3 d after infecting mice with polyomavirus, we fixed the splenocytes and measured the presentation of LT359-368 by H-2D b by incubating cells with the available MHC class I-restricted mouse hybridoma HLT359 (Fig. 6b) . Splenocytes from Ace −/− mice infected with PyV.OVA-I elicited lower responses than did those from Ace +/+ mice infected with PyV.OVA-I, consistent with the results of the LT359-368-specific T cell response. We also measured the surface expression of H-2K b -SKL on the splenocytes with antibody 25-D1.16 (specific for the H-K b -SKL complex). We also stained the cells with antibody to the common myeloid marker CD11b and antibody to the common DC marker CD11c to distinguish APCs (Fig. 6c) . Not unexpectedly, CD11c + DCs were more efficient at presenting SKL than were CD11b + CD11c − myeloid cells. However, both populations of Ace −/− cells were less efficient at presenting SKL than were their Ace +/+ counterparts. Thus, we conclude that ACE can also affect the presentation of virus-expressed antigens by MHC class I.
ACE works as a carboxyl dipeptidase on proteasomal products
To elucidate the biochemical activity of ACE in the setting of antigen processing, we made use of SKL as the model epitope (peptides, Supplementary Table 1 ). In L.K b cells transfected with a 'minigene' expressing SKL, cotransfection of a construct expressing ACE did not affect the presentation of SKL (Fig. 7a) . However, when the penultimate lysine of SKL was replaced with histidine (SHL), a residue more easily cleaved by ACE 28 , cotransfection of the construct expressing ACE in L.K b cells resulted in less presentation of SHL, assessed as IL-2 production by the B3Z mouse T cell hybridoma incubated together with the L.K b cells 29 . ACE expression also significantly enhanced the presentation of SKL-TE, an SKL precursor with an extension of two amino acids at the C terminus. Not unexpectedly, ACE 10 macrophages overexpressing ACE were more efficient at processing the SKL-TE peptide than were Ace +/+ macrophages ( Fig. 7b and  Supplementary Fig. 9a ). Amide modification of the C terminus can block monopeptidase activity. However, ACE 10 macrophages processed SKL-TE-amide almost as efficiently as they processed SKL-TE, whereas ACE 10 and Ace +/+ macrophages had a similar ability to present SKL-T (SKL with an extension of one amino acid at the C terminus). These experiments verified that ACE works as a carboxyl dipeptidase in processing MHC class I antigens. ACE did not work as an aminopeptidase, as Ace −/− , Ace +/+ and ACE 10 macrophages were equivalent in the processing of E-SKL and LE-SKL (SKL with an extension of one amino acid (E-SKL) or two amino acids (LE-SKL) at the amino (N) terminus) when we transfected those by nucleofection as minigenes (Supplementary Fig. 9b ). Furthermore, the use of SKL precursors with extension at the N terminus showed that ACE expression did not seem to change the basic machinery of antigen presentation.
To directly assess the catalytic activity of ACE in processing SKL, SHL and SKL precursors with extension at the C terminus, we incubated individual peptides for 1 h with recombinant human ACE and analyzed the digestion products by liquid chromatography-mass spectrometry. ACE did not produce fragments with appreciable N-terminal truncation from any of the peptides. Although the two amino acids of SKL at the C terminus could be slowly removed by ACE in vitro, the efficiency of ACE in degrading SHL (SIINFEHL) to SIINFE was much superior (the ratio of the catalytic constant for SHL to that for SKL was 3.98; Supplementary Fig. 10a ). ACE was unable to digest SKL-T or SKL-TEWT (SKL with an extension of four amino acids at the C terminus), but it did remove the two amino acids at the C terminus of SKL-TE and SKL-TEW (SKL with an extension of three amino acids at the C terminus; Supplementary Fig. 10b,c) . For all the peptides tested, ACE did not remove the one, three or four amino acid(s) at the C terminus. These data were consistent with the results we obtained with the in vivo peptide-processing assays presented above and indicated that ACE is a carboxyl dipeptidase.
To verify that ACE edits MHC class I peptides through its catalytic domains and can function in the endoplasmic reticulum, we generated mutated ACE cDNA constructs encoding ACE that was either functionally inactive or could not enter the endoplasmic reticulum. The mACE protein used above was made by substitution of sequence in the two zinc-binding motifs of the ACE catalytic domains, from His-Glu-Met-Gly-His to Lys-Glu-Met-Gly-Lys (substitutions underlined) 30 . The mACE protein seemed to be expressed similarly to wild-type ACE in transfected cells, as assessed by flow cytometry (Supplementary Fig. 11a ). Only ACE, not mACE, enhanced the cleavage of SKL from SKL-TE and presentation of SKL by H-2K b in L.K b cells (Fig. 7c) . Next we made a truncated ACE (∆ACE) by removing the first 29 amino acids at the N terminus, which is the hydrophobic signal peptide 13 . We determined that ∆ACE was catalytically active because when L.K b cells were transfected with construct encoding ∆ACE, it helped them process SKL-TE ( Supplementary  Fig. 11b ). However, only ACE, not ∆ACE, enhanced the presentation of a SKL-TE encoded by a minigene containing sequence encoding an endoplasmic reticulum signal sequence when this was expressed in TAP-deficient RMA-S mouse tumor cells ( Fig. 7d) .
It is the proteasome that makes the bulk of the raw peptide pool for MHC class I presentation. However, some proteinases have been shown to expose antigenic peptides in a proteosome-independent manner 11 . We thus studied the relative contribution of the proteasome and ACE to the processing of ovalbumin protein or SKL-TE. When both ovalbumin and ACE were expressed in L.K b cells, the expression of ACE resulted in more presentation of SKL (Fig. 7e) . However, when proteasome activity was blocked with the proteasome inhibitor epoxomicin, SKL presentation by the degradation of ovalbumin was completely abrogated, whether ACE was present or not. In contrast, when SKL-TE was expressed in L.K b cells, ACE coexpression enhanced SKL presentation, and this was diminished but not eliminated by epoxomicin, consistent with published data showing that the proteasome can cleave the C terminus of extended peptide precursors 9 . These data suggest that ACE trims peptides produced first by proteasome activity.
DISCUSSION
Here we have shown that peptide presentation by MHC class I was different on the surface of ACE-deficient and wild-type cells. That conclusion was supported by cross-immunization studies and by analysis of TCR V β use, the expression patterns of minor histocompatibility antigens and viral antigen presentation. We identified a role for ACE in processing MHC class I peptides in macrophages, DCs and fibroblasts. Our data suggest that under physiological conditions, ACE actively participates in the intracellular processing of peptides for presentation by MHC class I. Furthermore, ACE serves a unique antigen-processing function in mice, as other enzymes apparently cannot compensate for the absence of ACE.
Published studies have examined C-terminal cleavage of MHC class I peptide precursors when proteasome activity is inhibited 9, [31] [32] [33] . Those studies led to the belief that only the proteasome affects the C terminus of MHC class I peptides and thus challenged the idea that carboxypeptidases are involved. However, given a subsequent publication 11 and now our analysis presented here, that idea seems untenable. Although we are not certain why the previously published studies did not detect carboxypeptidase activity, one possibility is that perhaps, unlike ERAP expression, ACE expression may be extremely low in the cell lines originally used to study this. For example, L cells 1 0 8 4 VOLUME 12 NUMBER 11 NOVEMBER 2011 nature immunology A r t i c l e s (a common cell line used in such studies) have only about 1% of the ACE mRNA present in macrophages and DCs (data not shown).
Those earlier experiments also neglected the possibility of inducible carboxypeptidase in 'professional' APCs, especially in the setting of inflammation. The predominant action of ACE is to cleave C-terminal dipeptides from oligopeptide substrates. ACE has wide substrate specificity. Some studies have shown that ACE can even remove C-terminal tripeptides (from substance P) and cleave N-terminal tripeptides (from luteinizing hormone-releasing hormone) 34 . However, the in vivo importance of these unusual ACE catalytic activities is not known. What is clear is that ACE can cleave peptides ranging from 3 amino acids (hippuryl-histidyl-leucine) 13 to over 40 amino acids (amyloid-β peptide) 35 . Because of this property, ACE may not work as a 'molecular ruler' in editing peptides for MHC class I loading, as is postulated for ERAP 36 .
We assessed the correlation between ACE expression and surface expression of MHC class I and found that of seven MHC class I molecules, four showed substantial inverse correlation to ACE abundance (H-2K b , H-2D b , H-2K d and H-2D k ). Expression of MHC class I on the cell surface depends on the assembly of MHC class I-peptide complexes in the endoplasmic reticulum and their stability. In ACEdeficient cells, the augmented expression of H-2K b and H-2D b was probably due to a more abundant peptide supply rather than to a slower dissociation rate of MHC class I-peptide complexes. This inverse correlation between ACE and peptide supply is not seen for ERAP or TAP. The unusual effect of ACE may result from the mechanism of peptide selection by TAP. Sequencing of MHC class I peptide motifs has shown that the C terminus is usually the conservative anchor residue 5 . TAP selects substrates when transporting peptides from the cytosol to the endoplasmic reticulum 37, 38 . Mouse TAP, in particular, has a propensity for peptides with hydrophobic residues at the C terminus 39, 40 , which in most cases matches the specificity of MHC class I. Thus, when an endoplasmic reticulum carboxypeptidase exists, it may be more destructive than constructive in determining the quantity of peptides suitable for presentation by MHC class I. Nonetheless, for any individual epitope, ACE action may increase, decrease or, presumably, not affect expression. In our studies, ACEdeficient mice immunized with wild-type cells produced a robust CD8 + T cell response to antigens found on wild-type cells. This indicates that a wild-type set of epitopes rely on ACE for exposure. Indeed, the induction of ACE in APCs by either IFN-γ or L. monocytogenes indicates a physiological advantage during immunologic challenge. Given the considerable sensitivity of T cells in detecting presented epitopes, the advantage of increasing peptide diversity may outweigh the disadvantage of a somewhat smaller number of particular epitopes.
Finally, we note that either ACE depletion or ACE overexpression changed immunogenicity. Millions of patients are treated with ACE inhibitors. Future studies should determine whether the concentrations of these drugs are sufficient to have any effect on the amount of surface MHC class I or peptide presentation by MHC class I.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
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